Waltham, Mass. — BostonGene has been named the overall winner and an Outstanding Organization in the 2026 Artificial Intelligence Excellence Awards, while also receiving a product award for its multimodal artificial intelligence platform.
The awards, presented by the Business Intelligence Group, recognize BostonGene’s use of AI to support clinical trial design, patient selection and precision medicine development.
BostonGene develops AI-based models that combine genomic, transcriptomic, immune profiling, imaging and clinical data to help pharmaceutical and biotechnology companies identify predictive biomarkers, better understand treatment response and resistance, and make development decisions.
The company said its technology has been used in programs with global pharmaceutical partners to support translational research, biomarker strategies and decision-making across the research and development lifecycle.
“BostonGene stood out as an Outstanding Organization because its work reflects exactly where the market is headed: practical, biologically grounded AI that delivers immense, measurable value across multiple categories,” said Russ Fordyce, Chief Recognition Officer of the Business Intelligence Group.
BostonGene’s platform is built around an immune-focused foundation model designed to analyze the interactions between tumors and the immune system. The company said the approach treats the immune system as a driver of therapeutic response rather than solely as a secondary biomarker.
The platform is intended to help drug developers assess patient heterogeneity, refine clinical development strategies and evaluate key decisions throughout clinical trials.
BostonGene said the platform was trained using billions of data points, including an immune profiling dataset containing more than 18,000 blood samples.
The company’s research has been evaluated in independent patient groups and presented at scientific meetings including the American Society of Clinical Oncology, American Association for Cancer Research, American Society of Hematology, Society for Immunotherapy of Cancer and European Society for Medical Oncology.
Its findings have also appeared in peer-reviewed journals including Cancer Cell, Blood and Nature.
“This recognition reflects the depth of science our team has built and the trust our clinical and biopharma partners place in us,” said Nathan Fowler, M.D., Chief Medical Officer at BostonGene.
“Our goal is to help pharmaceutical companies make better development decisions by combining multimodal biology, deep tumor and immune system understanding, and biologically grounded AI,” Fowler said. “By providing a clearer view of patient biology, we help identify opportunities earlier, reduce development risk, and increase the probability of clinical success.”
